Member Info for SYN00GOLD

Thought I was the only one buying :-)

I am considering a little top up...……………………..my brain says no, but my heart is gut instinct says lump in :-)

Still great LTH :-)

All quiet is all good.

Gonna be a helluva ride on the Helium chase !!

Good luck everyone :-)

Great post GKB47 :-)

Targeting very specifically is key :-)

The Phase 3 results will put the 'fire out' on the negativity and gloom. This drug will be stockpiled by Governments globally as an insurance policy against next pandemic. Who could have forecast such as tiny little virion could wreak such havoc on our world. I look forward to the brilliant, Lancet published Phase 3 results showing the above !!

Also, the BoD are certainly not fools, yes, they have taken a large chunk of cash BUT only in stock and with condition attached to the SP. All is well, the pipeline is great and big Pharma will also be sniffing around some of this pipeline.

Have a wonderful week and enjoy the spring sunshine :-)

Me thinks the SP will rise sharply after this presentation/Q&A = I am getting as many shares as I possibly can, filled up yesterday and will hold these lovely little nuggets till SP > £1.50

Great opportunity, DO NOT kick yourself next week :-)

Great research Sangiju and good recap- I recall you buying @ 1.78 a few months ago, so obviously a great value share at current SP.

I wish you the best of luck with your investments. This share will rise quickly from these current levels.

Always do your own research. Don't believe anything written on an anonymous BB !

Been in and out of TILS since summer of 2018. Some great candidates :-)

Just purchased a few !! Looks like potentially good drugs and targets.

With all this crying, must be worth a punt !

Could be right ……………………..???? Mmmmmmm

from here as the release of the Phase 3 global trial results are anticipated. The ACTIV-2 could potentially drop the price slightly IF results from that trial show 'no statistical significance' as already been discussed and then the rise of the SP will steadily build.
My confidence in this forecast is 100%.
II's have done their DD a long time ago and the £1.75p was heavily oversubscribed. The science is rock solid. Still consider a TO is a strong possibility before the P3 output.

For my it is just a matter of biding one's time. Time to switch off and enjoy the summer.

The rewards will materialise both for investors and more importantly, long term for Earth in a broad spectrum viral agnostic antiviral drug targeting a specific group.

I wish everyone well for the summer.

Completely agree TLW - RM's message was extremely clear. The home trial was very useful. Sometimes, what are perceived as poor results need to be viewed in context. These results from the HT have given detailed and specific targets for the future. This is not to say that it was irrelevant. Treating people at home/ sending patients home from hospital earlier will be most beneficial to health providers globally.

Doc - I also agree with your assertion that the target is the Global Phase 3 output as this will target the hospital setting and will definitely show massive benefit. To me, SNG is not just about the current pandemic. The team are conducting themselves extremely well in challenging circumstances. Potentially the Activ-2 may show something very similar to the HT. This will not dissuade the FDA, far from it. All this 'build' of evidence is extremely useful.
What Synairgen have achieved is remarkable for anyone who understands Pharm dev and the timelines.

I do understand folks frustration, but the SP will take care of itself and I guess we will end up with either a TO or multiple JV's.

Very confident of massive success in H2. Good luck to all investors.

Using your own exact words whilst others panicking on the ARB BB recently...…...

'Relax, you are in too deep if this is getting to you.'

Using your own exact words whilst others panicking on the ARB BB recently...…...

'Relax, you are in too deep if this is getting to you.'

30 April 2021 RNS :

The degree of breathlessness at start of treatment indicates which patients should be treated with SNG001 both in hospital and at home
- Analysis of the combined data from the Hospital and Home Cohorts showed that the more breathless patients are significantly more likely (>3 fold) to recover on inhaled interferon beta (SNG001) than placebo
- The study results reinforce confidence in ongoing Phase III study, with data readout on track for H2 2021

Richard Marsden, CEO of Synairgen, said: "I am delighted by the finding that SNG001 treatment led to a threefold likelihood of recovery to 'no limitation of activities' in the markedly/severely breathless population compared to those on placebo in the home and hospital setting, and that further analyses reinforce our previous findings. It increases our conviction in the approach we have taken to conduct an international Phase III trial in hospitalised patients requiring supplemental oxygen, which is scheduled to read out in the second half of this year.

Professor Tom Wilkinson, Professor of Respiratory Medicine at the University of Southampton, commented: "The SG016 COVID-19 trial of inhaled interferon beta has been very successful. Although the vast majority of non-hospitalised patients had very mild symptoms, the effects of SNG001 on the small group of markedly and severely breathless patients indicated who might be benefitting most from SNG001. Assessment of breathlessness as a predictor of protracted recovery in the combined Home and Hospital Cohorts showed us that non-breathless patients have no need for the innate immune response boost that interferon beta provides, whereas the patients who were breathless derive strong benefit from SNG001. This tells us that we should target SNG001 at COVID-19 patients with marked or severe breathlessness where it has a potentially significant benefit."

My assessment : The Activ-2 may need tweaking based on above output to target more directly the most 'at need' patients
Global Phase 3 bang on track and will produce stunning results. Then we will see all the big Pharma boys biting Synairgen's hand off. Also suspect that this 30% share decline over past few weeks is a result of nervous PI's, whilst the large institutional investment companies will be quietly building their portfolio's (most under the radar thresholds)

Patience will serve all LTHolders well :-)

Public Health England (PHE) has been tracking a variant known as B.1.617.2, which appears to have been spreading more quickly in the UK than others.
Scientists believe it is more transmissible than the version of Covid first discovered in Wuhan, China.

https://www.bbc.co.uk/news/health-57016110

Phase 3 will be a superb outcome for shareholders (if not taken over before then!)

Hoooooooooolllldddddddddddddddd and accumulate for me.

I tend to agree somewhat with some of the sentiment regarding the release of information from the SYN team. I feel that communication could be improved.

However, as the fundamentals have not changed one iota (other than, the targeting is now more specific) which P3 is covering, I have just sold some other holdings and significantly topped up my holding at this ludicrously low current SP.

Thanks Tony T for your analysis. Good luck Synners :-)

Tonlin - You will be rewarded with this share. Patience is a virtue.

Stay strong Synners and ignore the 'noise' :-)